SCHEMBL19958765

SCHEMBL19958765

CC(NN)c1ccc(Cl)cc1Cl

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.62
TP53 P04637 2/20 0.62
HTT P42858 2/20 0.62
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
MAPT P10636 3/20 0.44
POLB P06746 1/20 0.44
IDO1 P14902 1/20 0.41
TDO2 P48775 1/20 0.41
RAB9A P51151 1/20 0.41
CYP3A4 P08684 1/20 0.40
TSHR P16473 1/20 0.40
KDM4E B2RXH2 1/20 0.39
MAPK1 P28482 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
HTR2A P28223 1/20 0.37
SLC6A4 P31645 1/20 0.37
KCNH2 Q12809 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19832462 1.00 LMNA (0.62) LMNATP53HTTMEN1KMT2A
Hydrochloric Acid SCHEMBL19816294 0.98 LMNA (0.60) LMNATP53HTTMEN1KMT2A
Hydrochloric Acid SCHEMBL30399840 0.98 LMNA (0.60) LMNATP53HTTMEN1KMT2A
Hydrochloric Acid SCHEMBL19947097 0.98 LMNA (0.60) LMNATP53HTTMEN1KMT2A
Hydrochloric Acid SCHEMBL19816297 0.98 LMNA (0.60) LMNATP53HTTMEN1KMT2A
SCHEMBL8210156 0.83 LMNA (0.67) LMNATP53HTTMEN1KMT2A
SCHEMBL8353840 0.82 LMNA (0.59) LMNATP53HTTMEN1KMT2A
SCHEMBL19965517 0.82 LMNA (0.59) LMNATP53HTTMEN1KMT2A
SCHEMBL8298242 0.82 LMNA (0.59) LMNATP53HTTMEN1KMT2A
SCHEMBL19832461 0.81 HTT (0.44) LMNATP53HTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10246462-B2 Chemokine receptor modulators and uses thereof FLX BIO, INC. (US) 2019-04-02 US disclosed
US-20180072743-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF RAPT THERAPEUTICS, INC. 2018-03-15 US disclosed
WO-2018049271-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF FLX BIO, INC. (US) 2018-03-15 WO disclosed
US-20180072743-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF RAPT THERAPEUTICS, INC. 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10246462-B2 Chemokine receptor modulators and uses thereof ACKR3, CCR5, CXCR3 LMNA 4833/4885TP53 3229/4885HTT 4765/4885
US-20180072743-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF ACKR3, CCR5, CXCR3 LMNA 4833/4885TP53 3229/4885HTT 4765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.